Table 1 Baseline Clinical Characteristics of the Study Population
Characteristics | (n = 63) |
|---|---|
Age, median (range) | 63 (42–80) |
Sex (male: female) | 51:12 |
Smoking history | |
Never smoker | 19 (30.2%) |
Past smoker | 22 (34.9%) |
Current smoker | 22 (34.9%) |
Stage at initial diagnosis of NSCLC | |
I–III | 16 (25.4%) |
IV | 47 (74.6%) |
Time between diagnosis and initiation of ICI (months, mean ± standard deviation) | 20.7 ± 34.14 |
Histology | |
Adenocarcinoma | 44 (69.8%) |
Squamous cell carcinoma | 14 (22.2%) |
Others* | 5 (7.9%) |
Previous CNS treatment** | |
None | 16 (25.4%) |
Surgery | 7 (11.1%) |
Local radiotherapy (GKRS or CKRS) | 44 (69.8%) |
WBRT (≥ 3 months prior to immunotherapy) | 4 (6.3%) |
CNS local treatment during immunotherapy | |
None | 42 (66.7%) |
Surgery | 0 (0%) |
Local radiotherapy (GKRS or CKRS) | 20 (31.7%) |
WBRT | 1 (1.6%) |
Type of immunotherapy | |
Pembrolizumab | 27 (42.9%) |
Nivolumab | 18 (28.6%) |
Atezolizumab | 18 (28.6%) |